Further, an anti-progranulin antibody (anti-PGRN monoclonal antibody A23) has been shown to reduce tumor growth and stabilize disease in cases of hepatocellular carcinoma in non-candidates for surgery [43]. This evidence concerns the gene GRN and hepatocellular carcinoma.